Just – Evotec Biologics Advances Orthopoxvirus into Phase 1 Clinical Studies

Just – Evotec Biologics, the Seattle-based biologics CDMO subsidiary of Evotec SE, announced the initiation of a Phase 1 clinical study evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed under the U.S. Department of War’s Accelerated Antibodies Program.